UNSPSC 51161561: Pirquinozol

This classification denotes an anti-asthmatic agent with the molecular formula C11H9N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D16HG4V2UC, chemically known as 2-(hydroxymethyl)pyrazolo(1,5-c)quinazolin-5(6h)-one but generally known as pirquinozol, which bears US NIH Compound Identifier 47783. European Medicines Agency schedules Pirquinozol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09941MIG.

UNSPSC 51161561 Pirquinozol, a Commodity code, encompasses generic multi-source pharmaceuticals and over-the-counter products that state and local government facilities procure through cooperative purchasing vehicles and direct supply agreements. State and local governments under this code buy pharmaceuticals with specific National Drug Codes (NDCs), SKUs, and packaging configurations distributed through authorized pharmaceutical wholesalers to support health and human services operations across participating jurisdictions. Issuing bodies include state health agencies, departments of administration managing cooperative purchasing alliances, and participating local government facilities. The procurement vehicle here is a multistate cooperative purchasing alliance, which aggregates demand across multiple jurisdictions and establishes framework agreements with manufacturers to supply both generic and brand-name pharmaceutical products at negotiated pricing.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with response due March 26, 2026. The solicitation requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and mandates cGMP certification, Drug Supply Chain Security Act (DSCSA) compliance, and contractual relationships with at least two of the three designated wholesalers. Award criteria weight price competitiveness at 75 percent, with evaluation also covering fixed pricing structure (10 percent), EDI capability (5 percent), and administrative compliance (10 percent combined). The contract term runs two years for new responders through June 30, 2028, with MMCAP reserving the right to make sole, dual, or multi-awards based on therapeutic considerations and member-specific needs. Geographic scope includes Minnesota and Oregon participating facilities, with products required to be available in the marketplace by May 15, 2026.